Healthcare Services

Pediatric Brain Tumors Market Revenue Growth Expected to Reach $1.92 Billion by 2030 with 6.6% CAGR

April 3, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Valuation Is Forecasted For The Pediatric Brain Tumors Market By 2030 Starting From Its 2026 Size?

The pediatric brain tumors market has shown substantial growth in recent years. It is projected to increase from $1.4 billion in 2025 to $1.49 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.9%. The market’s historical growth can be attributed to factors such as limited awareness of pediatric brain tumors, a continued reliance on conventional therapies, low adoption rates for advanced imaging techniques, a scarcity of specialized pediatric neuro-oncology centers, and the restricted availability of targeted and immunotherapy treatments.

The market for pediatric brain tumors is projected to experience robust expansion over the coming years. By 2030, this market is anticipated to reach a value of $1.93 billion, exhibiting a compound annual growth rate (CAGR) of 6.6%. This anticipated growth is primarily driven by factors such as the rising occurrence of pediatric brain tumors, the expanding implementation of precision medicine, the increased incorporation of AI and digital imaging in diagnostic procedures, a heightened emphasis on individualized treatment strategies, and greater financial support for pediatric neuro-oncology research. Key developments expected within this period involve the enhanced uptake of precision medicine specifically for pediatric brain tumors, the growing integration of digital imaging and AI-powered diagnostic tools, the expanding application of targeted therapies and immunotherapies, an increased concentration on surgical methods that are minimally invasive, and a surge in investment directed towards pediatric neuro-oncology research.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21248&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Pediatric Brain Tumors Market?

The increasing demand for personalized medicine is projected to propel the growth of the pediatric brain tumors market going forward. Personalized medicine is a healthcare strategy that customizes treatments and medical decisions based on an individual’s genetic makeup, lifestyle, and unique health requirements. The demand for this approach is rising due to advancements in genetic research, improved diagnostic tools, and the potential for more effective and targeted treatments. By tailoring therapies to a child’s specific tumor type, mutation, and response, personalized medicine enables targeted interventions that are more effective and cause less damage to healthy tissue, enhancing outcomes and reducing side effects. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based hospital and health care organization, the FDA approved 16 new personalized treatments for rare disease patients in 2023, an increase from six in 2022. Therefore, the growing demand for personalized medicine is driving the expansion of the pediatric brain tumor market.

Which Segment Categories Define The Pediatric Brain Tumors Market?

The pediatric brain tumors market covered in this report is segmented –

1) By Type: Gliomas, Mixed Neuronal-Glial Tumors, Embryonal Tumors, Choroid Plexus Papilloma Or Carcinoma, Tumors Arising From Non-Neuroepithelial Tissue, Meningeal Tumors

2) By Treatment Type: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Immunotherapy

3) By Diagnosis Method: Imaging Techniques, Biopsy, Neurological Exam, Lumbar Puncture

4) By Age Group: Infants, Toddlers, Children, Adolescents

5) By Application: Hospitals And Clinics, Medical Research Centers, Academic Institutes, Other Applications

Subsegments:

1) By Gliomas: Low-Grade Gliomas, High-Grade Gliomas

2) By Mixed Neuronal-Glial Tumors: Gangliogliomas, Dysembryoplastic Neuroepithelial Tumors (DNET)

3) By Embryonal Tumors: Medulloblastoma, Atypical Teratoid Rhabdoid Tumor (ATRT), Primitive Neuroectodermal Tumors (PNET)

4) By Choroid Plexus Papilloma Or Carcinoma: Choroid Plexus Papilloma, Choroid Plexus Carcinoma

5) By Tumors Arising From Non-Neuroepithelial Tissue: Rhabdomyosarcoma, Ewing’s Sarcoma

6) By Meningeal Tumors: Meningiomas, Hemangiopericytomas

How Are Trends Shaping The Direction Of The Pediatric Brain Tumors Market?

Major companies operating within the pediatric brain tumors market are increasingly concentrating on creating advanced therapeutic options, including type II RAF inhibitors, to improve targeted treatments and patient outcomes. Type II RAF inhibitors function as precise therapies designed to hinder RAF kinases, especially those with mutations that promote tumor proliferation. These inhibitors specifically target abnormal RAF protein structures identified in certain pediatric low-grade glioma (pLGG) subtypes, thereby effectively interrupting the faulty signaling pathways crucial for tumor cell growth and survival. A notable instance occurred in April 2024, when Day One Biopharmaceuticals, a US-based biotechnology company, declared that the U.S. Food and Drug Administration (FDA) had bestowed accelerated approval upon OJEMDA (tovorafenib) for the treatment of relapsed or refractory pediatric low-grade glioma (pLGG) in patients aged 6 months and older presenting with specific BRAF alterations. OJEMDA consequently becomes the first FDA-sanctioned therapy specifically targeting BRAF fusions or mutations in this patient group. The decision for approval was underpinned by an overall response rate of 51% documented during the FIREFLY-1 clinical trial, which assessed the drug’s efficacy for this indication. This treatment is particularly intended for children whose brain tumors have not responded to earlier interventions.

Who Are The Top Companies Competing In The Pediatric Brain Tumors Market?

Major companies operating in the pediatric brain tumors market are Bayer AG, Novartis AG, Roche Holding AG, Takeda Pharmaceutical Company, UCLA Health, Novocure, Blueprint Medicines, Oncoheroes Biosciences, Plus Therapeutics Inc., Stemline Therapeutics Inc., BrainChild Bio Inc., Seattle Children’s Therapeutics, Pfizer Inc., Merck & Co Inc., Bristol Myers Squibb Company, Sanofi, Amgen Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Eli Lilly and Company, Day One Biopharmaceuticals Inc., Biodexa Pharmaceuticals, Cellectar Biosciences Inc., ZIOPHARM Oncology Inc., Y-mAbs Therapeutics Inc., Neonc Technologies Inc.

Read the full pediatric brain tumors market report here:

https://www.thebusinessresearchcompany.com/report/pediatric-brain-tumors-global-market-report

Which Regions Are Projected To Dominate The Pediatric Brain Tumors Market In The Coming Years?

North America was the largest region in the pediatric brain tumors market in 2025. The regions covered in the pediatric brain tumors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Pediatric Brain Tumors Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21248&type=smp

Browse Through More Reports Similar to the Global Pediatric Brain Tumors Market 2026, By The Business Research Company

Overactive Bladder Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/overactive-bladder-treatment-global-market-report

Urinary Tract Infection Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/urinary-tract-infection-treatment-global-market-report

Bladder Cancer Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/bladder-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795